Home :: Health :: Cystitis

Latest Cystitis News

MediciNova Announces Completion of Enrollment in a Phase II ... - PR Newswire (press release)

SAN DIEGO, Feb. 6 /PRNewswire/ -- MediciNova, Inc., a specialty pharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced completion of enrollment of 297 patients with relapsing Multiple Sclerosis (MS) in its Phase II clinical trial of MN-166. MN-166 is a novel, orally administered compound being evaluated for the treatment of MS. In July 2005, MediciNova initiated a randomized, double-blind, placebo-controlled multi-center Phase II clinical trial of MN-166 in MS patients in Eastern Europe. Two hundred and ninety-seven (297) patients have been randomized to receive placebo or One of two doses of MN-166 in this trial. Efficacy data is expected after One year of treatment (in this two year trial) in 1Q07. MN-166 inhibits leukotriene activity, phosphodiesterases and nitric oxide synthase, all inflammatory mechanisms known to be involved in MS. Recently, MN-166 was found to have beneficial effects in several pilot clinical trials conducted in MS patients in Japan. These findings led to the issuance of a new U.S. method of use patent for MN-166 in 2002. "MN-166 may be an effective new approach to treating MS with the added advantage of oral dosing. Rapid completion of enrollment in - More available

Cystitis

No Ebay Marketplace Listings Found